1. 4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
2. Blaston
3. Cidine
4. Cinitapride Tartrate
1. 66564-14-5
2. Paxapride
3. Cidine
4. Cinitapride [inn]
5. Cinitapride Hydrogen Tartrate
6. 4-amino-n-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
7. R8i97i2l24
8. 66564-14-5 (free Base)
9. Cinitapride (inn)
10. 4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
11. Cinitaprida
12. Cinitapridum
13. Cinitapridum [inn-latin]
14. Cinitaprida [inn-spanish]
15. Cidin
16. Unii-r8i97i2l24
17. Paxapride (tn)
18. Cinitapride [mi]
19. 96623-56-2
20. Cinitapride [mart.]
21. (non-labelled)cinitapride-d5
22. Cinitapride [who-dd]
23. Schembl476454
24. Chembl2104523
25. Schembl19235643
26. Dtxsid60867232
27. Chebi:135642
28. Bcp04096
29. Hy-b2089
30. Akos015909742
31. Bcp9000531
32. Db08810
33. Bcp0726000107
34. Cs-0017505
35. Ft-0665049
36. D07700
37. Q5121012
1. Cas 66564-14-5
| Molecular Weight | 402.5 g/mol |
|---|---|
| Molecular Formula | C21H30N4O4 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 113 |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 586 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
It is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease (GERD), non-ulcer dyspepsia and delayed gastric emptying.
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03F - Propulsives
A03FA - Propulsives
A03FA08 - Cinitapride
Absorption
The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing.
3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.
Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.
